Latest short-term investments for RUBY: $4.1M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (December 2022), RUBY shows a short-term investments of $4.1M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, RUBY's short-term investments is now $4.1M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Rubius Therapeutics is outperforming or lagging.
Tracking RUBY's short-term investments over time shows whether Rubius Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $4.1M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this short-term investments page, Stockcircle has Rubius Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect short-term investments (currently $4.1M) with ownership activity and broader fundamentals.
Rubius Therapeutics's short-term investments is $4.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.